Wesley Lane, MD
Cardiovascular Disease · Little Rock, ARNPI 1013276187
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (30.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Abbott accounts for 65.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $31,264 and has fallen 94.8% since, to $1,624 in 2025. Among cardiovascular disease clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $144.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$30K
- Shockwave Medical, Inc$9K
- Edwards Lifesciences$2K
- Boston Scientific$2K
- Medtronic$810
- Abiomed$546
- plus $2K from 21 others
What the payments were for
- Consulting fees$11,37525%
- Speaking & faculty fees$8,60019%
- Travel & lodging$13,98231%
- Food & beverage$11,52225%
- Other$2821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 160 | $29,849 |
| Shockwave Medical, Inc | 15 | $9,053 |
| Edwards Lifesciences | 13 | $1,855 |
| Boston Scientific | 30 | $1,799 |
| Medtronic(2 entities) | 14 | $810 |
| Abiomed | 7 | $546 |
| Pfizer | 29 | $486 |
| Novartis | 14 | $225 |
| Avinger Inc. | 2 | $218 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Asahi Intecc USA, Inc. | 1 | $97 |
| Livanova USA, Inc. | 1 | $95 |
| Inari Medical, Inc. | 3 | $74 |
| Amgen | 4 | $73 |
| Penumbra, Inc. | 1 | $66 |
| Biotronik Inc. | 3 | $61 |
| AstraZeneca | 3 | $56 |
| Cardiva Medical, Inc. | 1 | $51 |
| Inspire Medical Systems, Inc. | 1 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $38 |
| Biosense Webster, Inc. | 1 | $35 |
| Novo Nordisk | 1 | $29 |
| Cordis US CORP. | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| Merck | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NAVITOR$18,301
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,820
- MitraClip$3,018
- PORTICO$2,442
- Watchman$1,035
- AMPLATZER AMULET$427
- CoreValve Evolut$421
- Impella$281
- MitraClip System$247
- Xience V coronary stent system$223
- PANTHERIS$218
- Optis Coronary Imaging System$168
- Portico Transcatheter Aortic Heart Valve$160
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$147
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$130
- Mitra Clip system$122
- COREVALVE EVOLUT R$121
- Edwards SAPIEN 3 Transcatheter Heart Valve$109
- GENERAL - STRUCTURAL HEART$101
How this compares
$45,761 in reported general payments places this provider in the 90th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 499 | $410,707 |
| EntrestoSacubitril/Valsartan | 294 | $248,813 |
| XareltoRivaroxaban | 95 | $69,701 |
| Repatha SureclickEvolocumab | 53 | $41,232 |
| FarxigaDapagliflozin Propanediol | 34 | $33,744 |
| JardianceEmpagliflozin | 34 | $29,930 |
| MounjaroTirzepatide | 14 | $15,358 |
| Prasugrel Hcl | 90 | $9,112 |
| BrilintaTicagrelor | 16 | $8,750 |
| ClopidogrelClopidogrel Bisulfate | 906 | $8,266 |
| Rosuvastatin Calcium | 763 | $8,102 |
| Ranolazine ErRanolazine | 105 | $7,924 |
| NexletolBempedoic Acid | 12 | $5,584 |
| Metoprolol Succinate | 401 | $4,489 |
| Potassium Chloride | 269 | $4,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $486 | $410,707499 claims |
| NovartisEntresto | $225 | $248,813294 claims |
| Johnson & JohnsonXarelto | $14 | $69,70195 claims |
| AstraZenecaFarxiga, Brilinta | $56 | $42,49450 claims |
| Boehringer IngelheimJardiance | $21 | $29,93034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
- Michael HuberLittle Rock$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.